Application of PGF2α at the moment of fixed-time artificial insemination in crossbred beef cows

Abstract

Although studies have shown positive effects of gonadotropin releasing hormone (GnRH) or prostaglandin F 2α (PGF 2α ) at the moment of fixed-time artificial insemination (FTAI) in the conception rate (CR) of cattle, its effects on treatments based on progesterone (P4) and estradiol benzoate (EB) is still not conclusive. The objective of this study was (1) to evaluate the effect of a PGF 2α analogue at FTAI in the CR of crossbred beef cows submitted to a 11d FTAI protocol based on P4 and EB; and (2) to describe the CR between PGF 2α -treated and control cows in different body condition scores (BCS) and parity categories. Crossbred (½ Nellore and ½ Angus) beef cows were submitted to a synchronization protocol and randomly assigned into 2 groups: Control (n = 163), at FTAI cows received 2 mL of saline solution as a placebo, and PGF 2α (n = 163), at FTAI cows were treated with PGF 2α analogue (10 mg of dinoprost tromethamine). Pregnancy diagnosis was performed 33d post-FTAI. Binary logistic regression model was used to analyze the effect of PGF 2α treatment on CR. There was no difference in CR between PGF 2α and control groups (P > 0.05; odds ratio (OR) = 0.92; confidence interval (CI) = 0.59-1.4). A greater CR was found in heifers (P = 0.0006, OR = 2.65, CI = 1.61 -4.38) and multiparous (P = 0.0006, OR = 2.12, CI = 1.04 -4.3) when compared to primiparous cows. Cows with low BCS (4; 9-point scale) showed lower CR when compared with moderate BCS (5-6; 9-point scale) (P < 0.05; OR = 0.10; CI = 0.06 -0.18). There was no numerical difference on CR between PGF 2α -treated and control cows in different BCS and parity categories. The results suggested that the CR in this study was not influenced by 10 mg PGF 2α analogue at FTAI.

Mesenchymal stem cells in animal reproduction: sources, uses and scenario

“…Around days 5 to 9 of the protocol (D5 to D9), the device is removed, and subsequently, a dose of prostaglandin (PGF2α) is administered. The purpose of PGF2α application, and its analogs, is luteolytic action, occurring within 48 hours after application (Santos Marques et al, 2022).…”